Youssef Mahdi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Youssef Mahdi has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Basma El Khannoussi
Pathology Department, Oncology National Institute, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
4 shared publications - Mouna Khmou
Pathology Department, Faculty of Medicine and Pharmacy, Oncology National Institute, Mohammed V University, Rabat 10100, Morocco
3 shared publications - Soumaya Ech-Charif
Pathology Department, Oncology National Institute, Faculty of Medicine and Pharmacy, Mohammed V University, Rabat, Morocco
3 shared publications A. Jahid
Université Mohammed V
2 shared publications- Ahmed Jahid
Department of Pathology, Ibn Sina University Hospital, Rabat, Morocco
2 shared publications Chaimaa Mounjid
Department of Pathology and Molecular Pathology, National Institute of Oncology, Rabat, Morocco
2 shared publications
Latest Publications
- Open Access
- 21 September 2026
- Published by Springer Nature in Diagnostic Pathology
Decentralized homologous recombination deficiency (HRD) testing in advanced high-grade serous ovarian carcinoma: real-world implementation and molecular profiling from Morocco
Background: Homologous Recombination Deficiency (HRD) testing guides poly (ADP-ribose) polymerase inhibitor (PARPi) therapy in high-grade serous ovarian carcinoma (HGSOC). Centralized commercial assays pose logistical and financial barriers in low- and middle-income countries (LMICs). This study evaluated the pathological validation, clinical implementation, molecular landscape, and feasibility of a decentralized HRD testing platform in North Africa. Materials and methods: This real-world cohort study enrolled 215 advanced HGSOC patients at the National Institute of Oncology in Rabat, Morocco (March 2024–March 2026). Following strict histopathological selection (tumor cellularity ≥ 20%, necrosis < 30%), local genomic profiling utilized an in-house next-generation sequencing (NGS) pipeline (Oncomine Comprehensive Assay Plus) on formalin-fixed paraffin-embedded (FFPE) tumor tissue. HRD positivity was defined by a genomic instability metric (GIM) score ≥ 16. Objective pre-analytical metrics were defined to categorize testing failures. Results: Pre-analytical quality control failed in 57/215 samples (26.5%). DNA degradation ( n = 40, 70.2% of failures) was driven by real-world pre-analytical variability in decentralized workflows, while low DNA yield ( n = 17, 29.8% of failures) was linked to small core needle biopsies with low tumor cellularity or extensive stromal fibrosis. Among 158 evaluable patients, 87 (55.1%) were HRD-positive; 57.5% (50/87) harbored BRCA1/2 mutations and 42.5% (37/87) were BRCA wild-type. HRD prevalence significantly associated with age ( p = 0.017), peaking at 69.4% (50–59 years) and dropping to 32.1% (≥ 70 years). Confrontation of TP53 NGS data with immunohistochemical (IHC) reflex testing on NGS wild-type cases ( n = 27) identified 19 cases with aberrant p53 staining patterns, raising the total rate of p53 abnormalities to 94.9% (150/158). Average turnaround time was three weeks. One test represented 37.1% of the country’s annual Gross Domestic Product (GDP) per capita and over 400% of the monthly minimum wage. Conclusions: Local, decentralized testing is clinically viable in resource-limited settings. Addressing pre-analytical tissue processing quality and conducting formal health-economic evaluations are essential to ensuring sustainable access to precision oncology across LMICs.
- 21 September 2026
- Published by Springer Nature in Diagnostic Pathology
Open AccessDecentralized homologous recombination deficiency (HRD) testing in advanced high-grade serous ovarian carcinoma: real-world implementation and molecular profiling from Morocco
Background: Homologous Recombination Deficiency (HRD) testing guides poly (ADP-ribose) polymerase inhibitor (PARPi) therapy in high-grade serous ovarian carcinoma (HGSOC). Centralized commercial assays pose logistical and financial barriers in low- and middle-income countries (LMICs). This study evaluated the pathological validation, clinical implementation, molecular landscape, and feasibility of a decentralized HRD testing platform in North Africa. Materials and methods: This real-world cohort study enrolled 215 advanced HGSOC patients at the National Institute of Oncology in Rabat, Morocco (March 2024–March 2026). Following strict histopathological selection (tumor cellularity ≥ 20%, necrosis < 30%), local genomic profiling utilized an in-house next-generation sequencing (NGS) pipeline (Oncomine Comprehensive Assay Plus) on formalin-fixed paraffin-embedded (FFPE) tumor tissue. HRD positivity was defined by a genomic instability metric (GIM) score ≥ 16. Objective pre-analytical metrics were defined to categorize testing failures. Results: Pre-analytical quality control failed in 57/215 samples (26.5%). DNA degradation ( n = 40, 70.2% of failures) was driven by real-world pre-analytical variability in decentralized workflows, while low DNA yield ( n = 17, 29.8% of failures) was linked to small core needle biopsies with low tumor cellularity or extensive stromal fibrosis. Among 158 evaluable patients, 87 (55.1%) were HRD-positive; 57.5% (50/87) harbored BRCA1/2 mutations and 42.5% (37/87) were BRCA wild-type. HRD prevalence significantly associated with age ( p = 0.017), peaking at 69.4% (50–59 years) and dropping to 32.1% (≥ 70 years). Confrontation of TP53 NGS data with immunohistochemical (IHC) reflex testing on NGS wild-type cases ( n = 27) identified 19 cases with aberrant p53 staining patterns, raising the total rate of p53 abnormalities to 94.9% (150/158). Average turnaround time was three weeks. One test represented 37.1% of the country’s annual Gross Domestic Product (GDP) per capita and over 400% of the monthly minimum wage. Conclusions: Local, decentralized testing is clinically viable in resource-limited settings. Addressing pre-analytical tissue processing quality and conducting formal health-economic evaluations are essential to ensuring sustainable access to precision oncology across LMICs.
- Open Access
- 14 April 2026
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 138 (5) , 1754-1759
Beyond the image: achieving complete pathologic response in MSI-high metastatic colon cancer despite persistent PET activity
Background: Microsatellite instability-high (MSI-H) colorectal cancer, presents high tumor mutational burden and is highly responsive to immune checkpoint inhibitors (ICIs). ICIs have transformed metastatic colorectal cancer (mCRC) treatment. However, the role of partial or discontinued immunotherapy and the interpretation of PET imaging in this setting remain challenging. Objective: We aim to report a case of MSI-H mCRC with liver metastasis demonstrating complete pathological response after partial immunotherapy despite persistent PET activity, highlighting integrative approaches of immunotherapy and surgery. Case presentation: A 49-year-old female with MSI-H left colon adenocarcinoma and a single liver metastasis underwent laparoscopic subtotal colectomy, followed by chemotherapy (FOLFOX plus bevacizumab) combined with pembrolizumab. Immunotherapy was discontinued after four cycles due to limited resources. PET-CT after chemotherapy showed persistent metabolic activity in liver lesions. She underwent surgical segmentectomy with negative margins. Final pathology showed no residual tumor. Discussion: Partial immunotherapy can induce profound pathological response in MSI-H mCRC. Persistent PET positivity may reflect immune-related inflammation rather than viable tumor, complicating response assessment. Combined immunotherapy and surgery improve survival in MSI-H metastatic disease. Emerging evidence supports tailored immunotherapy duration and multidisciplinary management. Conclusion: Partial immunotherapy in MSI-H metastatic colon cancer can achieve complete pathological remission despite PET persistence. Surgery remains vital for definitive response assessment and cure. Multimodal strategies integrating systemic immunotherapy and local treatment optimize outcomes for MSI-H mCRC patients.
- 14 April 2026
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 138 (5) , 1754-1759
Open AccessBeyond the image: achieving complete pathologic response in MSI-high metastatic colon cancer despite persistent PET activity
Background: Microsatellite instability-high (MSI-H) colorectal cancer, presents high tumor mutational burden and is highly responsive to immune checkpoint inhibitors (ICIs). ICIs have transformed metastatic colorectal cancer (mCRC) treatment. However, the role of partial or discontinued immunotherapy and the interpretation of PET imaging in this setting remain challenging. Objective: We aim to report a case of MSI-H mCRC with liver metastasis demonstrating complete pathological response after partial immunotherapy despite persistent PET activity, highlighting integrative approaches of immunotherapy and surgery. Case presentation: A 49-year-old female with MSI-H left colon adenocarcinoma and a single liver metastasis underwent laparoscopic subtotal colectomy, followed by chemotherapy (FOLFOX plus bevacizumab) combined with pembrolizumab. Immunotherapy was discontinued after four cycles due to limited resources. PET-CT after chemotherapy showed persistent metabolic activity in liver lesions. She underwent surgical segmentectomy with negative margins. Final pathology showed no residual tumor. Discussion: Partial immunotherapy can induce profound pathological response in MSI-H mCRC. Persistent PET positivity may reflect immune-related inflammation rather than viable tumor, complicating response assessment. Combined immunotherapy and surgery improve survival in MSI-H metastatic disease. Emerging evidence supports tailored immunotherapy duration and multidisciplinary management. Conclusion: Partial immunotherapy in MSI-H metastatic colon cancer can achieve complete pathological remission despite PET persistence. Surgery remains vital for definitive response assessment and cure. Multimodal strategies integrating systemic immunotherapy and local treatment optimize outcomes for MSI-H mCRC patients.
- Open Access
- 21 December 2024
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2025 (1) , rjaf025
Mesonephric-like adenocarcinoma of the ovary: a case study
Mesonephric-like adenocarcinoma (MLA) is a rare and newly recognized subtype of ovarian and endometrial carcinomas, introduced in the 2020 World Health Organization Classification. This tumor likely originates from Müllerian-derived tissues and often mimics more common ovarian cancers, leading to frequent misdiagnosis. This case study details a 36-year-old woman who presented with urinary symptoms following a hysterectomy. Imaging revealed a significant left ovarian mass, initially misdiagnosed as carcinosarcoma. Pathological evaluation ultimately confirmed MLA, characterized by diverse architectural patterns and specific immunohistochemical markers. The patient underwent chemotherapy due to the locally advanced disease. This case highlights the diagnostic challenges of MLA and emphasizes the need for awareness among clinicians to prevent misdiagnosis. Given its aggressive nature and tendency to early recurrence, further research is essential for establishing standardized diagnostic criteria and treatment protocols for this rare malignancy.
- 21 December 2024
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2025 (1) , rjaf025
Open AccessMesonephric-like adenocarcinoma of the ovary: a case study
Mesonephric-like adenocarcinoma (MLA) is a rare and newly recognized subtype of ovarian and endometrial carcinomas, introduced in the 2020 World Health Organization Classification. This tumor likely originates from Müllerian-derived tissues and often mimics more common ovarian cancers, leading to frequent misdiagnosis. This case study details a 36-year-old woman who presented with urinary symptoms following a hysterectomy. Imaging revealed a significant left ovarian mass, initially misdiagnosed as carcinosarcoma. Pathological evaluation ultimately confirmed MLA, characterized by diverse architectural patterns and specific immunohistochemical markers. The patient underwent chemotherapy due to the locally advanced disease. This case highlights the diagnostic challenges of MLA and emphasizes the need for awareness among clinicians to prevent misdiagnosis. Given its aggressive nature and tendency to early recurrence, further research is essential for establishing standardized diagnostic criteria and treatment protocols for this rare malignancy.
- Open Access
- 5 June 2023
- Published by Springer Nature in BMC Gastroenterology
- Vol. 23 (1) , 1-7
Correlation between KRAS and NRAS mutational status and clinicopathological features in 414 cases of metastatic colorectal cancer in Morocco: the largest North African case series
Background: Advances in molecular biology have improved understanding of the molecular features of carcinogenesis and progression of colorectal cancer. It is clear that the efficacy of anti-EGFR depends upon the RAS mutational status, since any mutation in RAS is associated with resistance to anti-EGFR therapy. The aim of this study is to report the largest North African description of KRAS and NRAS status in metastatic colorectal cancer and to describe the association of these mutations with clinicopathological characteristics. Methods: This is a prospective study of all consecutive unselected metastatic colorectal cancer samples, collected from the Laboratory of Pathology at the National Institute of Oncology of Rabat, Morocco, from January 1st 2020 to December 31st 2021. The molecular analysis was performed on the Idylla™ platform (fully automated real-time polymerase chain reaction-based assay) for KRAS and NRAS mutations in exons 2, 3 and 4. These mutations were correlated to gender, primary tumor site, histological type and degree of differentiation of tumor using adequate statistical methods. Results: Four hundred fourteen colorectal tumors were screened for KRAS and NRAS mutations. These mutations occurred in 51.7% of tumors for KRAS (mainly in exon 12) and in 3% of tumors for NRAS. There was a significant correlation between NRAS mutation and age of colorectal patients in this study. The low rate of invalid RAS tests (1.7% for KRAS and 3.1% for NRAS) was certainly obtained due to the strict respect of pre-analytical factors such as cold ischemia time and formalin fixation. Conclusion: We report the largest North African analysis of NRAS and KRAS status in colorectal metastatic patients. This study showed the ability in low middle income countries to perform a high rate of valid tests and the unusual trend towards older patients for NRAS mutations.
- 5 June 2023
- Published by Springer Nature in BMC Gastroenterology
- Vol. 23 (1) , 1-7
Open AccessCorrelation between KRAS and NRAS mutational status and clinicopathological features in 414 cases of metastatic colorectal cancer in Morocco: the largest North African case series
Background: Advances in molecular biology have improved understanding of the molecular features of carcinogenesis and progression of colorectal cancer. It is clear that the efficacy of anti-EGFR depends upon the RAS mutational status, since any mutation in RAS is associated with resistance to anti-EGFR therapy. The aim of this study is to report the largest North African description of KRAS and NRAS status in metastatic colorectal cancer and to describe the association of these mutations with clinicopathological characteristics. Methods: This is a prospective study of all consecutive unselected metastatic colorectal cancer samples, collected from the Laboratory of Pathology at the National Institute of Oncology of Rabat, Morocco, from January 1st 2020 to December 31st 2021. The molecular analysis was performed on the Idylla™ platform (fully automated real-time polymerase chain reaction-based assay) for KRAS and NRAS mutations in exons 2, 3 and 4. These mutations were correlated to gender, primary tumor site, histological type and degree of differentiation of tumor using adequate statistical methods. Results: Four hundred fourteen colorectal tumors were screened for KRAS and NRAS mutations. These mutations occurred in 51.7% of tumors for KRAS (mainly in exon 12) and in 3% of tumors for NRAS. There was a significant correlation between NRAS mutation and age of colorectal patients in this study. The low rate of invalid RAS tests (1.7% for KRAS and 3.1% for NRAS) was certainly obtained due to the strict respect of pre-analytical factors such as cold ischemia time and formalin fixation. Conclusion: We report the largest North African analysis of NRAS and KRAS status in colorectal metastatic patients. This study showed the ability in low middle income countries to perform a high rate of valid tests and the unusual trend towards older patients for NRAS mutations.
- Open Access
- 18 May 2022
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2022 (5) , rjac233
An unusual variant of lipoma: case report
Osteo-lipoma is a very rare benign tumor with a good prognosis. It is composed mainly of mature fatty tissue with a bony component. The diagnosis is based on the histological study, given the clinical and radiological characters that can simulate other benign or malignant pathologies. Osteosarcoma is the main differential diagnosis. The distinction between these two neoplasms is essential as the basis of the treatment is different. We report the case of a patient with a giant ossifying lipoma independent of bone tissue located in the thigh.
- 18 May 2022
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2022 (5) , rjac233
Open AccessAn unusual variant of lipoma: case report
Osteo-lipoma is a very rare benign tumor with a good prognosis. It is composed mainly of mature fatty tissue with a bony component. The diagnosis is based on the histological study, given the clinical and radiological characters that can simulate other benign or malignant pathologies. Osteosarcoma is the main differential diagnosis. The distinction between these two neoplasms is essential as the basis of the treatment is different. We report the case of a patient with a giant ossifying lipoma independent of bone tissue located in the thigh.
- Open Access
- 30 April 2022
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2022 (4) , rjac116
Breast metastasis 18 years after nephrectomy for renal cell carcinoma: a case report
Metastasis of renal clear cell carcinoma (RCC) to the breast is exceptional. Breast metastases of extra-mammary tumors are rare and usually involve melanoma, lymphoma or leukemia. We report the case of a patient with breast metastasis of renal clear cell carcinoma occurring 18 years after nephrectomy. A history of RCC should always raise suspicion about breast metastasis, a situation that remains exceptional and whose diagnosis relies on anatomopathology.
- 30 April 2022
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2022 (4) , rjac116
Open AccessBreast metastasis 18 years after nephrectomy for renal cell carcinoma: a case report
Metastasis of renal clear cell carcinoma (RCC) to the breast is exceptional. Breast metastases of extra-mammary tumors are rare and usually involve melanoma, lymphoma or leukemia. We report the case of a patient with breast metastasis of renal clear cell carcinoma occurring 18 years after nephrectomy. A history of RCC should always raise suspicion about breast metastasis, a situation that remains exceptional and whose diagnosis relies on anatomopathology.
- Open Access
- 22 August 2018
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 12 (1) , 1-6
Diagnostic difficulties of primary angiosarcoma of the breast: a case report
Angiosarcoma of the breast is a rare tumor, which may be primary or secondary to breast surgery or irradiation. It is characterized by polymorphic and nonspecific clinical and radiological features. A pathologist plays a key role in positive and differential diagnosis and in establishing the prognosis: only a histological examination can confirm the diagnosis, and the histologic grade is the most important prognostic factor. In fact, angiosarcomas of the breast constitute a very heterogeneous group and they are classified into three grades based on the degree of differentiation. We will illustrate diagnostic challenges through this new case of primary angiosarcoma of the breast. Microscopic findings were initially interpreted as a benign vascular tumor. We will also discuss the relevant medical literature. A 56-year-old Arabian woman presented with a palpable right breast mass that had been enlarging for 2 months, measuring 5 cm, without axillary lymphadenopathy. She had no personal or family history of breast surgery or breast irradiation. A mammography showed no evidence of spiculation. No suspicious calcifications were seen. A needle core biopsy was performed. Microscopic findings were initially interpreted as a benign vascular tumor. However, as the mass measured 5 cm, the diagnosis of angiosarcoma was more appropriate, and mastectomy without axillary dissection was performed. Microscopic examination found mild to moderately scattered pleomorphic cells, and scattered mitotic figures. It also showed papillary formations, solid foci of spindle cells, and hemorrhagic necrosis. The margins of the tumor were infiltrative. The diagnosis of primary intermediately differentiated angiosarcoma of the breast (grade II) was made. No distant metastases were found. Our patient was lost to follow-up and further treatment after mastectomy until she developed local tumor progression 4 months later. Through this case report, we emphasize the importance of clinicopathological confrontation in angiosarcoma of the breast.
- 22 August 2018
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 12 (1) , 1-6
Open AccessDiagnostic difficulties of primary angiosarcoma of the breast: a case report
Angiosarcoma of the breast is a rare tumor, which may be primary or secondary to breast surgery or irradiation. It is characterized by polymorphic and nonspecific clinical and radiological features. A pathologist plays a key role in positive and differential diagnosis and in establishing the prognosis: only a histological examination can confirm the diagnosis, and the histologic grade is the most important prognostic factor. In fact, angiosarcomas of the breast constitute a very heterogeneous group and they are classified into three grades based on the degree of differentiation. We will illustrate diagnostic challenges through this new case of primary angiosarcoma of the breast. Microscopic findings were initially interpreted as a benign vascular tumor. We will also discuss the relevant medical literature. A 56-year-old Arabian woman presented with a palpable right breast mass that had been enlarging for 2 months, measuring 5 cm, without axillary lymphadenopathy. She had no personal or family history of breast surgery or breast irradiation. A mammography showed no evidence of spiculation. No suspicious calcifications were seen. A needle core biopsy was performed. Microscopic findings were initially interpreted as a benign vascular tumor. However, as the mass measured 5 cm, the diagnosis of angiosarcoma was more appropriate, and mastectomy without axillary dissection was performed. Microscopic examination found mild to moderately scattered pleomorphic cells, and scattered mitotic figures. It also showed papillary formations, solid foci of spindle cells, and hemorrhagic necrosis. The margins of the tumor were infiltrative. The diagnosis of primary intermediately differentiated angiosarcoma of the breast (grade II) was made. No distant metastases were found. Our patient was lost to follow-up and further treatment after mastectomy until she developed local tumor progression 4 months later. Through this case report, we emphasize the importance of clinicopathological confrontation in angiosarcoma of the breast.
- Open Access
- 2 August 2018
- Published by Springer Nature in BMC Clinical Pathology
- Vol. 18 (1) , 6
Diagnostic pitfall: primary myoepithelial carcinoma of the lacrimal gland, case report and literature review
In lacrimal gland, lymphomas and inflammatory lesions predominate. Primary epithelial tumours represent less than 30% of lacrimal gland lesions. Myoepithelial carcinoma of lacrimal gland is rare. To the best of our knowledge, only nine cases have been reported in the literature. This lesion presents diagnostic difficulties: non-specific clinical and radiological findings and histological polymorphism. This is well illustrated by the diagnostic pathology errors described in the literature. We report a new case of lacrimal myoepithelial carcinoma with a review of others published cases to try to assess clinico-pathological features and outcome whenever possible of this rare tumour. An 80-year-old Arabian female presented with a 2-month history of swelling over the right eyebrow, pain, proptosis of the right eye and diplopia. Computed tomography demonstrated an ill-defined, homogeneous, contrast-enhancing mass attached to the medial rectus. A biopsy was performed. Microscopic examination showed malignant spindle cells tumour, most consistently to sarcoma or sarcomatoid carcinoma. Immunohistochemical study was not possible because neoplastic material has been exhausted. Subsequently, total exenteration of the right orbit was performed. Immunohistochemical study revealed diffuse positive staining for pancytokeratin AE1/AE3, epithelial membrane antigen (EMA) and smooth muscle actin (SMA) and focal positivity for S100 protein. The lesion was immunonegative for desmin, h-cladesmon, CD34, Melan-A and HMB-45. The tumour was extending to the surgical margins. The patient was lost to follow-up until she developed local tumour progression 3 months after removal. The patient was again lost to follow-up and therefore did not receive any other treatment in our hospital. We present this rare tumour with an unusual location. The use of a complete immunohistochemical panel with epithelial and myoepithelial markers positivity helped us for classification of this poorly differentiated tumour.
- 2 August 2018
- Published by Springer Nature in BMC Clinical Pathology
- Vol. 18 (1) , 6
Open AccessDiagnostic pitfall: primary myoepithelial carcinoma of the lacrimal gland, case report and literature review
In lacrimal gland, lymphomas and inflammatory lesions predominate. Primary epithelial tumours represent less than 30% of lacrimal gland lesions. Myoepithelial carcinoma of lacrimal gland is rare. To the best of our knowledge, only nine cases have been reported in the literature. This lesion presents diagnostic difficulties: non-specific clinical and radiological findings and histological polymorphism. This is well illustrated by the diagnostic pathology errors described in the literature. We report a new case of lacrimal myoepithelial carcinoma with a review of others published cases to try to assess clinico-pathological features and outcome whenever possible of this rare tumour. An 80-year-old Arabian female presented with a 2-month history of swelling over the right eyebrow, pain, proptosis of the right eye and diplopia. Computed tomography demonstrated an ill-defined, homogeneous, contrast-enhancing mass attached to the medial rectus. A biopsy was performed. Microscopic examination showed malignant spindle cells tumour, most consistently to sarcoma or sarcomatoid carcinoma. Immunohistochemical study was not possible because neoplastic material has been exhausted. Subsequently, total exenteration of the right orbit was performed. Immunohistochemical study revealed diffuse positive staining for pancytokeratin AE1/AE3, epithelial membrane antigen (EMA) and smooth muscle actin (SMA) and focal positivity for S100 protein. The lesion was immunonegative for desmin, h-cladesmon, CD34, Melan-A and HMB-45. The tumour was extending to the surgical margins. The patient was lost to follow-up until she developed local tumour progression 3 months after removal. The patient was again lost to follow-up and therefore did not receive any other treatment in our hospital. We present this rare tumour with an unusual location. The use of a complete immunohistochemical panel with epithelial and myoepithelial markers positivity helped us for classification of this poorly differentiated tumour.
- 1 June 2015
- Published by Elsevier in Archives de Pédiatrie
- Vol. 22 (6) , 661-664
Lymphome B inclassable, entre lymphome B diffus à grandes cellules et lymphome de Burkitt
- 1 June 2015
- Published by Elsevier in Archives de Pédiatrie
- Vol. 22 (6) , 661-664
Lymphome B inclassable, entre lymphome B diffus à grandes cellules et lymphome de Burkitt
- Open Access
- 2 May 2015
- Published by Springer Nature in Diagnostic Pathology
- Vol. 10 (1) , 1-5
Primary atypical teratoid/rhabdoid tumor of the optic nerve: a rare entity in an exceptional location
Atypical teratoid/rhabdoid tumors are rare and highly malignant central nervous system tumors. They have no specific radiological features and often present several histological components that make a problem in differential diagnosis with medulloblastoma and primitive neuroectodermal tumors. We present the case of a newborn girl complained of a gradual proptosis of the left eye secondary to an expansive lesional process of the optic nerve. The location at the optic nerve, reported only twice in the literature, and an exclusive rhabdoid appearance on biopsy added additional differential diagnosis problems. The proptosis worsened and the infant died few days after two cycles of chemotherapy. The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2037718783145212 .
- 2 May 2015
- Published by Springer Nature in Diagnostic Pathology
- Vol. 10 (1) , 1-5
Open AccessPrimary atypical teratoid/rhabdoid tumor of the optic nerve: a rare entity in an exceptional location
Atypical teratoid/rhabdoid tumors are rare and highly malignant central nervous system tumors. They have no specific radiological features and often present several histological components that make a problem in differential diagnosis with medulloblastoma and primitive neuroectodermal tumors. We present the case of a newborn girl complained of a gradual proptosis of the left eye secondary to an expansive lesional process of the optic nerve. The location at the optic nerve, reported only twice in the literature, and an exclusive rhabdoid appearance on biopsy added additional differential diagnosis problems. The proptosis worsened and the infant died few days after two cycles of chemotherapy. The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/2037718783145212 .